RxDoctor Payments Data

Steven Krause, DO

Interventional Cardiology · Quincy, ILNPI 1386628519

Payments from drug & device makers

$3,706in general payments, 2019–2025

Across 187 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novartis$530
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$350
  • Medtronic$197
  • Shockwave Medical, Inc$172
  • Johnson & Johnson$155
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$78921%
  • Food & beverage$2,90378%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,706 in reported general payments places this provider in the 25th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$264,087
Medicare patients
1,946
Services billed
4,348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban388$467,135
EntrestoSacubitril/Valsartan132$200,188
XareltoRivaroxaban153$184,699
Repatha SureclickEvolocumab85$66,461
JardianceEmpagliflozin40$47,897
Praluent PenAlirocumab37$20,431
Repatha SyringeEvolocumab19$15,825
BrilintaTicagrelor21$12,304
Dofetilide22$11,729
Ezetimibe369$10,548
Metoprolol Succinate702$9,187
Rosuvastatin Calcium246$5,971
Atorvastatin Calcium653$5,386
Pantoprazole Sodium371$4,463
ClopidogrelClopidogrel Bisulfate233$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$467,135388 claims
NovartisEntresto$530$200,188132 claims
Johnson & JohnsonXarelto$155$184,699153 claims
Boehringer IngelheimJardiance$55$47,89740 claims
AstraZenecaBrilinta$86$12,30421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Quincy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →